Back to Journals » Cancer Management and Research » Volume 11

Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era

Authors Liu S, Shi J, Guo H, Xu F, Wei M, Sun K, Chen Y

Received 17 August 2019

Accepted for publication 10 October 2019

Published 5 November 2019 Volume 2019:11 Pages 9409—9420

DOI https://doi.org/10.2147/CMAR.S227671

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Dr Eileen O'Reilly


Siwei Liu,1 Jie Shi,2 Honggang Guo,2 Fangfang Xu,2 Min Wei,1 Kai Sun,2 Yuqing Chen2

1Department of Hematology, Henan University People’s Hospital, School of Clinical Medicine, Henan University, Zhengzhou 450003, Henan, People’s Republic of China; 2Department of Hematology, Henan Provincial People’s Hospital, Zhengzhou 450003, Henan, People’s Republic of China

Correspondence: Yuqing Chen
Department of Hematology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, #7 Weiwu Road, Zhengzhou, Henan 450003, People’s Republic of China
Tel +86-13633812912
Fax +86371-65580875
Email henanblood@sina.com
Kai Sun
Department of Hematology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, #7 Weiwu Road, Zhengzhou, Henan 450003, People’s Republic of China
Tel +86-18237110038
Email sunkai@cellscience.org

Purpose: Red blood cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), and platelet count (PLT) have been reported to be associated with the prognosis of malignancies; this study aimed to evaluate the prognostic significance of the inflammatory prognostic scoring index (IPSI), comprised of RDW, N LR, and PLT for overall survival (OS) in newly diagnosed multiple myeloma patients in the bortezomib-based chemotherapy era.
Patients and methods: The prognostic significance of variables associated with the OS of 175 newly diagnosed multiple myeloma patients was evaluated through univariate and multivariate analyses. The cut-off values of RDW, NLR, and PLT were obtained from references. Patients with high RDW (RDW>14) were given a score of 1; patients with high NLR (NLR>2) or low PLT (PLT≤150) were given a score of 2. According to the obtained scores, the inflammatory prognostic scoring index (IPSI) was formed, in which patients were grouped into high-risk group (4–5 points), intermediate-risk group (3 points) and low-risk group (0–2 points).
Results: OS varied significantly in different IPSI groups (P< 0.001). On multivariate analysis, the IPSI was an independent prognostic factor for OS (intermediate-risk group HR 2.89, 95% CI 1.60–5.22, high risk-group HR 14.50, 95% CI 7.26–28.93, P<0.001). Importantly, with IPSI as supplement to the International Staging System (ISS), a significant difference in OS was observed among IPSI subgroups (ISS I, P<0.001; ISS II, P=0.008; ISS III, P<0.001).
Conclusion: The IPSI, comprised of RDW, NLR, and PLT, played specific role in the prognosis of patients preliminarily diagnosed with multiple myeloma in the bortezomib-based chemotherapy era and could be a beneficial supplement for ISS staging.

Keywords: multiple myeloma, red blood cell distribution width, neutrophil-to-lymphocyte ratio, platelet count, inflammatory prognostic scoring index

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]